

FOR IMMEDIATE RELEASE

Contact: John Wilkie

T 262-524-1402 ext. 111

E jwtwilkie@invivocorp.com

Invivo Introduces the Complete Clinical MR Prostate Solution - the DynaCAD for Prostate System and DynaTRIM (Trans-Rectal Interventional MRI)

PEWAUKEE, WI (June 30, 2009) - Invivo Corporation announced today its first-to-market MR prostate solution for analysis, planning and interventional biopsy. This complete clinical MR solution for prostate combines new DynaCAD for Prostate, an Advanced Clinical Visualization System, and new DynaTRIM, a device for the first MR-guided intervention application. The combined solution offers a truly new imaging and intervention option for many patients with elevated and/or rising PSA levels.

Over the past five years, strong collaborative relationships have been formed with Fox Chase Cancer Center, Philadelphia, PA, Radboud University of Nijmegen, The Netherlands, University of Chicago, IL, and Desert Medical Imaging, Indian Wells, CA. These clinical sites have assisted Invivo in the evaluation of this software with its comprehensive set of advanced prostate image visualization tools for performing real-time image analysis and interventional procedure planning. "DynaCAD for Prostate provides increased operational efficiency enabling the radiologist to rapidly interpret the 3,000 images that constitute a dynamic contrast enhanced prostate MRI." said John Feller, Chief Medical Officer at Desert Medical Imaging.

The Urologist faces the dilemma of patients with elevated and/or rising PSA levels and negative TRUS-guided biopsy results. The Invivo complete clinical MR prostate solution offers an alternative to keeping patients in an uncertain state. DynaTRIM enables the physician to conduct targeted MRI-guided interventions of the prostate gland reducing the number of cores acquired during biopsy. "Especially for patients that have had several sessions of biopsies with negative results; they only need a maximum of 4 MR-guided biopsies with a detection rate of 59%." according to Dr. Inge von Oort, Oncological Urologist, University of Medical Center Nijmegen, the Netherlands.

About Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common cancer, other than skin cancers, in American men and the second leading cause of cancer death behind lung cancer. Approximately 1 man in 6 will be diagnosed with prostate cancer during his lifetime and 1 in 35 will die. When patients present with an elevated PSA, many can go onto multiple TRUS-guided biopsies with negative results. Invivo believes this DynaCAD for Prostate and DynaTRIM can be an alternative for the appropriate patient population augmenting other diagnostic tools such as ultra sound.

About DynaCAD

DynaCAD is an advanced visualization system for viewing and analyzing MR images, providing physicians with a number of new tools for improving their workflow and throughput. With over 1,000 DynaCAD systems installed globally, DynaCAD is clinically used today for MR image analysis and breast biopsy interventional planning. The new DynaCAD for Prostate system is now available for new as well as existing DynaCAD system customers with Invivo's best-in-class technical support.

About Invivo

Invivo is the pioneer in innovative RF coils, Advanced Image Visualization Systems and MRI-compatible interventional instruments to increase MR image quality and analysis. Invivo is the world leader in MRI monitoring, providing accurate vital signs for improved patient safety. Invivo draws on its financial strength, operational excellence and technical leadership in the market of Magnetic Resonance Imaging (MRI), as well as its expanding businesses within Medical Devices. The Company has a more than 30-year history as a successful developer, manufacturer and marketer of high-value-added medical devices. For more information, visit www.invivocorp.com or call 800-331-3220.

=====